Literature DB >> 17580255

Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases.

Shigesaburo Miyakoshi1, Eiji Kusumi, Tomoko Matsumura, Akiko Hori, Naoko Murashige, Tamae Hamaki, Koichiro Yuji, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Yoshinobu Kanda, Masahiro Kami, Yuji Tanaka, Shuichi Taniguchi.   

Abstract

Invasive fungal infection (IFI) is a significant complication after allogeneic hematopoietic stem cell transplantation (HSCT); however, we have little information on its clinical features after reduced intensity cord blood transplantation (RICBT) for adults. We reviewed medical records of 128 patients who underwent RICBT at Toranomon Hospital between March 2002 and November 2005. Most of the patients received purine-analogbased preparative regimens. Graft-versus-host disease (GVHD) prophylaxis was a continuous infusion of either tacrolimus 0.03 mg/kg or cyclosporine 3 mg/kg. IFI was diagnosed according to the established EORTC/NIH-MSG criteria. IFI was diagnosed in 14 patients. Thirteen of the 14 had probable invasive pulmonary aspergillosis and the other had fungemia resulting from Trichosporon spp. Median onset of IFI was day 20 (range: 1-82), and no patients developed IFI after day 100. Three-year cumulative incidence of IA was 10.2%. Four of the 13 patients with invasive aspergillosis (IA) developed grade II-IV acute GVHD, and their IA was diagnosed before the onset of acute GVHD. The mortality rate of IFI was 86%. Multivariate analysis revealed that the use of prednisolone >0.2 mg/kg (relative risk 7.97, 95% confidence interval 2.24-28.4, P = .0014) was a significant risk factor for IA. This study suggests that IFI is an important cause of deaths after RICBT, and effective strategies are warranted to prevent IFI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580255     DOI: 10.1016/j.bbmt.2007.02.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

1.  How I transplant a patient with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-08-26       Impact factor: 22.113

2.  How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard E Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

3.  Successful treatment with combined chemotherapy of two adult cases of hemophagocytic lymphohistiocytosis in recipients of umbilical cord blood cell transplantation.

Authors:  Akiko Fukunaga; Fumiaki Nakamura; Noriyoshi Yoshinaga; Shojiro Inano; Wataru Maruyama; Hirokazu Hirata; Nobuyoshi Arima
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

4.  Death by edible mushroom: first report of Volvariella volvacea as an etiologic agent of invasive disease in a patient following double umbilical cord blood transplantation.

Authors:  R B Salit; Y R Shea; J Gea-Banacloche; G A Fahle; M Abu-Asab; J A Sugui; A E Carpenter; M M Quezado; M R Bishop; K J Kwon-Chung
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

5.  Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.

Authors:  Toshihiro Miyamoto; Shuichiro Takashima; Koji Kato; Ken Takase; Goichi Yoshimoto; Shuro Yoshida; Hideho Henzan; Koichi Osaki; Tomohiko Kamimura; Hiromi Iwasaki; Tetsuya Eto; Takanori Teshima; Koji Nagafuji; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-09-29       Impact factor: 2.490

Review 6.  Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint.

Authors:  E J Bow
Journal:  Mycopathologia       Date:  2009-04-03       Impact factor: 2.574

7.  A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.

Authors:  Shinsuke Takagi; Hideki Araoka; Naoyuki Uchida; Yumiko Uchida; Daisuke Kaji; Hikari Ota; Aya Nishida; Kazuya Ishiwata; Masanori Tsuji; Hisashi Yamamoto; Tadaaki Ito; Naofumi Matsuno; Go Yamamoto; Yuki Asano-Mori; Masahiro Hayashi; Koji Izutsu; Kazuhiro Masuoka; Atsushi Wake; Shigeyoshi Makino; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Int J Hematol       Date:  2014-03-25       Impact factor: 2.490

8.  Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.

Authors:  Julia A Brown; Kristen Stevenson; Haesook T Kim; Corey Cutler; Karen Ballen; Sean McDonough; Carol Reynolds; Maria Herrera; Deborah Liney; Vincent Ho; Grace Kao; Philippe Armand; John Koreth; Edwin Alyea; Steve McAfee; Eyal Attar; Bimalangshu Dey; Thomas Spitzer; Robert Soiffer; Jerome Ritz; Joseph H Antin; Vassiliki A Boussiotis
Journal:  Blood       Date:  2010-01-27       Impact factor: 22.113

Review 9.  Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.

Authors:  Juan Montoro; José Luis Piñana; Federico Moscardó; Jaime Sanz
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-18       Impact factor: 2.576

10.  Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation.

Authors:  Satoshi Hashino; Lena Morita; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Koh Izumiyama; Masakatsu Yonezumi; Koji Chiba; Takeshi Kondo; Masahiro Asaka
Journal:  Int J Hematol       Date:  2007-12-11       Impact factor: 2.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.